Cited 48 times in
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 이정일 | - |
dc.contributor.author | 이현웅 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 한광협 | - |
dc.contributor.author | 안상훈 | - |
dc.date.accessioned | 2020-09-30T16:43:55Z | - |
dc.date.available | 2020-09-30T16:43:55Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 0269-2813 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/179598 | - |
dc.description.abstract | Background: Anti-viral therapy is not indicated for patients with chronic hepatitis B (CHB) in the immune-tolerant phase. Aims: To investigate the cumulative incidence of phase change and hepatocellular carcinoma (HCC) and independent predictors for phase change in patients with CHB in immune-tolerant phase. Methods: In total, 946 patients in immune-tolerant phase, defined as hepatitis B e antigen positivity, HBV-DNA >20 000 IU/mL and alanine aminotransferase (ALT) ≤40 IU/L, between 1989 and 2017 were enrolled from eight institutes. Results: The mean age of study population (429 men and 517 women) was 36.7 years. The mean ALT and HBV-DNA levels were 24.6 IU/L and 8.50 log10 IU/mL, respectively. Of the study population, 476 (50.3%) patients remained in immune-tolerant phase throughout the study period (median: 63.6 months). The cumulative incidence rates of phase change and HCC at 10 years were 70.7% and 1.7%, respectively. Multivariate analyses revealed that HBV-DNA level >107 IU/mL was associated independently with a reduced risk of phase change (hazard ratio [HR] = 0.734, P = 0.008), whereas a high ALT level, above the cut-off recommended in the Korean Association for the Study of the Liver guidelines (34 IU/L for men and 30 IU/L for women), was associated independently with a greater risk of phase change (HR = 1.885, P < 0.001). Conclusions: The criterion of HBV-DNA level > 107 IU/mL may be useful to define immune-tolerant phase. In addition, an extremely low risk of HCC development was observed in patients with CHB in immune-tolerant phase. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Han Ah Lee | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | In Hee Kim | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Dong Hyun Sinn | - |
dc.contributor.googleauthor | Jung Hwan Yu | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.contributor.googleauthor | Chang Hun Lee | - |
dc.contributor.googleauthor | Won Young Tak | - |
dc.contributor.googleauthor | Young Oh Kweon | - |
dc.contributor.googleauthor | Wonseok Kang | - |
dc.contributor.googleauthor | Yong-Han Paik | - |
dc.contributor.googleauthor | Jin-Woo Lee | - |
dc.contributor.googleauthor | Sang Jun Suh | - |
dc.contributor.googleauthor | Young Kul Jung | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.identifier.doi | 10.1111/apt.15741 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A03122 | - |
dc.contributor.localId | A03292 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A04268 | - |
dc.contributor.localId | A02226 | - |
dc.relation.journalcode | J00061 | - |
dc.identifier.eissn | 1365-2036 | - |
dc.identifier.pmid | 32452564 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15741 | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 이관식 | - |
dc.contributor.affiliatedAuthor | 이정일 | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.citation.volume | 52 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 196 | - |
dc.citation.endPage | 204 | - |
dc.identifier.bibliographicCitation | ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.52(1) : 196-204, 2020-07 | - |
dc.identifier.rimsid | 67335 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.